Ascendiant Capital Markets Reiterates Strong Buy Rating, $3.75 PT on Solta Medical
In a report published Wednesday, Ascendiant Capital Markets reiterated its Strong Buy rating and $3.75 price target on Solta Medical (NASDAQ: SLTM).
Ascendiant Capital Markets noted, “Yesterday, Solta announced that it has entered into a definitive agreement to acquire privately-held Sound Surgical Technologies LLC. Sound Surgical markets a suite of products, which utilize ultrasound technology, that primarily target plastic surgeons who perform liposuction procedures. The lead product is the VASER Lipo device, which uses ultrasound to facilitate the removal of fat in a minimally invasive procedure that results in a faster recovery for the patient compared to traditional liposuction procedures. The VASERsmooth procedure uses the same device platform to address cellulite. The VASER Shape is a non-invasive body shaping product.”
Solta Medical closed on Tuesday at $2.62.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.